{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T16:35:31Z","timestamp":1790354131101,"version":"4.1.0"},"reference-count":25,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T00:00:00Z","timestamp":1768176000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Neoadjuvant immunotherapy combined with chemotherapy is an emerging strategy for improving outcomes in patients with locally advanced gastric cancer (LAGC). However, clinical evidence regarding the efficacy of serplulimab plus SOX chemotherapy and its immunologic correlates remains limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      In this prospective, single-center, phase II trial, patients with cT3-4N+M0 resectable gastric or gastroesophageal junction adenocarcinoma received three cycles of serplulimab combined with SOX chemotherapy, followed by D2 gastrectomy and adjuvant therapy. The primary endpoints were pathological complete response (pCR) and major pathological response (MPR). Circulating immune markers, including cytokines (e.g., IL-1\u03b2, TNF-\u03b1) and T-cell subsets (e.g., CD4\n                      <jats:sup>+<\/jats:sup>\n                      \/Treg ratio), were profiled longitudinally to evaluate immune remodeling during neoadjuvant therapy. The exploratory role of perioperative parenteral nutrition (PN) was also assessed.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Among the 33 enrolled patients, all underwent surgery and achieved R0 resection. The pCR and MPR rates were 21.21% and 36.36%, respectively. The 12-month event-free survival (EFS) rate was 82.20% (68.99-97.94). Patients achieving MPR exhibited elevated preoperative IL-1\u03b2 levels, a lower CD4\n                      <jats:sup>+<\/jats:sup>\n                      \/Treg ratio, and a higher Treg\/CD8+ ratio, suggesting that systemic immune activation may predict better pathological response. While PN transiently preserved lymphocytes and reduced inflammation preoperatively, it showed no sustained postoperative immune effect.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Neoadjuvant serplulimab plus SOX chemotherapy demonstrates promising efficacy in LAGC, with immunologic remodeling potentially serving as a predictor of treatment response. The identification of non-invasive, blood-based immune biomarkers may help guide future patient selection and therapeutic optimization. The ongoing phase III trial (NCT04139135) will validate the efficacy of this perioperative immunochemotherapy strategy in LAGC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2025.1702737","type":"journal-article","created":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T08:10:11Z","timestamp":1768205411000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Neoadjuvant serplulimab and SOX chemotherapy for locally advanced gastric cancer: pathological responses and systemic immune signatures from a phase II trial"],"prefix":"10.3389","volume":"16","author":[{"given":"Hongjie","family":"Zhan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingzhi","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weilin","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"B2","unstructured":"Cancer Today 2022\n          \n          \n          \n          2022"},{"key":"B3","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.jncc.2024.01.006","article-title":"Cancer Incidence and mortality in China, 2022","volume":"4","author":"Han","year":"2024","journal-title":"J Natl Cancer Cent"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15164114","article-title":"The present and future of neoadjuvant and adjuvant therapy for locally advanced gastric cancer","volume":"15","author":"Koerner","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jncc.2024.06.005","article-title":"Cancer survival statistics in China 2019-2021: A multicenter, population-based study","volume":"4","author":"Zeng","year":"2024","journal-title":"J Natl Cancer Cent"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1002\/cac2.12193","article-title":"The chinese society of clinical oncology (Csco): clinical guidelines for the diagnosis and treatment of gastric cancer, 2021","volume":"41","author":"Wang","year":"2021","journal-title":"Cancer Commun (Lond)"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(21)00297-7","article-title":"Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (Resolve): an open-label, superiority and non-inferiority, phase 3 randomised controlled trial","volume":"22","author":"Zhang","year":"2021","journal-title":"Lancet Oncol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3322\/caac.21820","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1200\/jco.23.00170","article-title":"Health-related quality of life with nivolumab plus chemotherapy versus chemotherapy in patients with advanced gastric\/gastroesophageal junction cancer or esophageal adenocarcinoma from checkmate 649","volume":"41","author":"Moehler","year":"2023","journal-title":"J Clin Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(23)02033-0","article-title":"Pembrolizumab plus trastuzumab and chemotherapy for her2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 keynote-811 randomised placebo-controlled trial","volume":"402","author":"Janjigian","year":"2023","journal-title":"Lancet"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.19918","article-title":"Sintilimab plus chemotherapy for unresectable gastric or gastroesophageal junction cancer: the orient-16 randomized clinical trial","volume":"330","author":"Xu","year":"2023","journal-title":"Jama"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(23)00541-7","article-title":"Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (Keynote-585): an interim analysis of the multicentre, double-blind, randomised phase 3 study","volume":"25","author":"Shitara","year":"2024","journal-title":"Lancet Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2022-0093","article-title":"Matterhorn: phase iii study of durvalumab plus flot chemotherapy in resectable gastric\/gastroesophageal junction cancer","volume":"18","author":"Janjigian","year":"2022","journal-title":"Future Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3390\/nu16111639","article-title":"Enteral nutrition in operated-on gastric cancer patients: an update","volume":"16","author":"Triantafillidis","year":"2024","journal-title":"Nutrients"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1080\/01635581.2022.2059089","article-title":"Malnutrition and weight loss as prognostic factors in the survival of patients with gastric cancer","volume":"74","author":"Nikniaz","year":"2022","journal-title":"Nutr Cancer"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3390\/pathogens13050357","article-title":"Gastric cancer, immunotherapy, and nutrition: the role of microbiota","volume":"13","author":"Raoul","year":"2024","journal-title":"Pathogens"},{"key":"B17","unstructured":"Nccn Clinical Practice Guidelines in Oncology: Gastric Cancer\n          \n          \n          \n          2024"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19940601)73:11<2680::aid-cncr2820731105>3.0.co;2-c","article-title":"Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma","volume":"73","author":"Mandard","year":"1994","journal-title":"Clinicopathol Correlations Cancer"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised recist guideline (Version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1200\/jco.22.00686","article-title":"Neoadjuvant nivolumab plus ipilimumab and adjuvant nivolumab in localized deficient mismatch repair\/microsatellite instability-high gastric or esophagogastric junction adenocarcinoma: the gercor neonipiga phase ii study","volume":"41","author":"Andr\u00e9","year":"2023","journal-title":"J Clin Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02721-w","article-title":"Perioperative toripalimab and chemotherapy in locally advanced gastric or gastro-esophageal junction cancer: A randomized phase 2 trial","volume":"30","author":"Yuan","year":"2024","journal-title":"Nat Med"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1097\/js9.0000000000000492","article-title":"Evolutionary patterns and research frontiers in neoadjuvant immunotherapy: A bibliometric analysis","volume":"109","author":"Jiang","year":"2023","journal-title":"Int J Surg"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-35431-x","article-title":"Neoadjuvant therapy with immune checkpoint blockade, antiangiogenesis, and chemotherapy for locally advanced gastric cancer","volume":"14","author":"Li","year":"2023","journal-title":"Nat Commun"},{"key":"B24","doi-asserted-by":"publisher","first-page":"33","DOI":"10.21037\/jgo-23-808","article-title":"Neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio as biomarkers to prognosticate survival in advanced gastric cancer patients in the era of immunotherapy: A systematic review and meta-analysis","volume":"15","author":"Matsas","year":"2024","journal-title":"J Gastrointest Oncol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1097\/MCO.0b013e3283499ae1","article-title":"Perioperative nutritional management in digestive tract surgery","volume":"14","author":"Gustafsson","year":"2011","journal-title":"Curr Opin Clin Nutr Metab Care"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1702737\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T08:10:13Z","timestamp":1768205413000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1702737\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,12]]},"references-count":25,"alternative-id":["10.3389\/fimmu.2025.1702737"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1702737","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,12]]},"article-number":"1702737"}}